搜尋結果
華歷簡奴
其他比賽
Eisai Co., Ltd.｜A human health care company. News Release. Latest News. Information. August 14, 2024. “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates. August 6, 2024. Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation. August 1, 2024.
2024年1月9日 · The U.S. Food and Drug Administration (FDA) granted traditional approval on July 6, 2023. In the U.S., treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
2024年7月31日 · Dual-acting lecanemab is the only early AD treatment widely available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury and death even after plaques have been cleared from the brain.
On August 15, 1889, in the village of Ito in a mountain gorge in Nyu, Fukui in central Japan, Kikuji Naito and his wife Fuji welcomed their sixth child and third son into the family. The child is Toyoji Naito—a boy who would one day found the Eisai Group. At age 15, Toyoji moved west to Osaka, where his career first began.
2020年1月10日 · Halaven is in the halichondrin class of microtubule dynamics inhibitors with a novel mechanism of action. Structurally, Halaven is a simplified and synthetically produced version of halichondrin B, a natural product isolated from the marine sponge halichondria okadai.
2019年7月17日 · July 17, 2019. Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that Eisai received New Drug Approval for Eisai’s in-house developed anticancer agent Halaven ® (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the global revenue of the anti-amyloid-beta protofibril antibody “LEQEMBI®” (generic name: lecanemab) in the first quarter of fiscal year 2024 (April 1, 2024 – June 30, 2024) was JPY 6.3 billion (pre-audit basis), which was approximately 2.2 times higher than t...
